Tag Archives: MRI

Polymers with dual fluorescent and magnetic imaging capabilities boost resolution of cancer detection tools

Molecular probes that selectively latch onto tumor cells and emit imaging signals can detect cancer without invasive procedures. These tools, however, have specific deficiencies. Fluorescent probes that image individual molecules have poor depth penetration into cells. The alternative, magnetic resonance imaging (MRI) probes, resolves cells in three dimensions but with low resolution. Bin Liu at the A*STAR Institute of Materials Research and Engineering, Singapore, and co-workers have now solved this problem with a biocompatible polymer that combines MRI and fluorescence imaging in a single molecular probe. …read more

Source: FULL ARTICLE at Phys.org

New Report: Forbes No. 1 Mainstream Media Source For Digital Marketers In Q2

By Cheryl Conner, Contributor

Online marketing and social media company LeadTail has just issued its newest research report: Social Media Insights: How Digital Marketers Engage on Twitter, Q2 2013. In an exclusive agreement, CEO Carter Hostelley offered me a look at the data several days in advance of the report, which is available now. The study examined 515 North American digital marketers from April 1 through June 30, 2013. This is the first year LeadTail has conducted this survey. The company conducted a similar report on marketing executives in May. Of the insights the new report offers, here was the piece of data that immediately caught my eye – Forty-five percent of the material digital marketers share comes from mainstream media. The top mainstream media source, based on the number of unique marketers who shared each source is Forbes. That data aligns with Forbes’ Editor Lewis Dvorkin’s note that Forbes is the Business audience leader as measured by the MRI 2012 report in July 2012, and passed 45 million unique visitors in January 2013, as measured by Omniture. According to the digital marketers surveyed, their top 25 mainstream media choices are as follows: …read more

Source: FULL ARTICLE at Forbes Latest

Capuano undergoes MRI, receives calf injection

By Ken Gurnick Dodgers pitcher Chris Capuano had an MRI and platelet-rich plasma injection Thursday in his injured calf muscle, the club announced. Capuano left Tuesday night’s game with a strained left calf muscle, which he said he originally felt stretching before last Thursday’s game in San Diego.

From: http://mlb.mlb.com/news/article.jsp?ymd=20130419&content_id=45221160&notebook_id=45235146&vkey=notebook_la&c_id=la

Pure gold nanoparticles can inhibit fat storage

(Phys.org) —New research reveals that pure gold nanoparticles found in everyday items such as personal care products, as well as drug delivery, MRI contrast agents and solar cells can inhibit adipose (fat) storage and lead to accelerated aging and wrinkling, slowed wound healing and the onset of diabetes. The researchers, led by Tatsiana Mironava, a visiting assistant professor in the Department of Chemical and Molecular Engineering at Stony Brook University, detail their research, “Gold nanoparticles cellular toxicity and recovery: Adipose Derived Stromal cells,” in the journal Nanotoxicology.

From: http://phys.org/news285528843.html

KYTHERA Biopharmaceuticals, Inc. Presents Positive Magnetic Resonance Imaging (MRI) Results from Pha

By Business Wirevia The Motley Fool

Filed under:

KYTHERA Biopharmaceuticals, Inc. Presents Positive Magnetic Resonance Imaging (MRI) Results from Phase IIb Study of ATX-101 in the Reduction of Submental Fat or “Double Chin”

Data presented at American Society of Aesthetic Plastic Surgery’s “The Aesthetic Meeting 2013” Session A Oral Presentation

NEW YORK–(BUSINESS WIRE)– KYTHERA Biopharmaceuticals, Inc. (NAS: KYTH) today presented positive results that found MRI measurements of patients treated with ATX-101 demonstrated a statistically significant reduction in submental fat (SMF), commonly known as double chin, during an oral session at The Aesthetic Meeting 2013, organized by the American Society for Aesthetic Plastic Surgery (ASAPS), April 11-16, New York, NY. MRI assessments were performed in the study as a quantifiable and objective measure of submental fat volume and thickness. The same study also demonstrated positive results based on validated clinician- and patient-reported outcome measures. The results are from a Phase IIb, multicenter, randomized, double-blind, placebo-controlled study (ATX-101-09-15) to evaluate the safety and efficacy of ATX-101, a potential first-in-class, non-surgical, injectable drug currently in Phase III clinical trials in the U.S. and Canada for the reduction of SMF.

“The MRI results of this study are exciting because they support efficacy results observed by physicians and patients from this and other clinical studies that showed a statistically significant reduction in fat under the chin with an injectable treatment,” said ATX-101 investigator, Leroy Young, M.D., FACS, a board-certified plastic surgeon in private practice in St. Louis, MO, and past president of the Aesthetic Surgery Education and Research Foundation (ASERF). “Patients also reported that the reduction in submental fat made them feel happier and less self-conscious about their appearance, which is what we strive to achieve in aesthetic medicine.”

ATX-101 is a proprietary formulation of synthetically-derived deoxycholic acid (DCA), which is an endogenous molecule that aids in the breakdown of dietary fat. Results from the Phase IIb study showed that patients treated with 2 mg/cm2 of ATX-101 demonstrated:

  • Reduction of submental fat
    • Patients achieved statistically significant reduction in submental fat thickness as measured from baseline vs. placebo based on MRI (p<0.05 and p<0.001, week 16 and 32, respectively)
  • Statistically significant improvement in self-evaluated visual and psychological impact of submental fat vs. placebo based on Patient-Reported Submental Fat Impact Scale (overall impact, p<0.001,

    From: http://www.dailyfinance.com/2013/04/13/kythera-biopharmaceuticals-inc-presents-positive-m/

‘How To Live With Your Parents’: Polly’s Claustrophobia Leads To Extreme MRI Reaction (VIDEO)

By The Huffington Post News Editors

Polly’s parents got a taste of real parenthood — apparently something her mother skipped out on when raising her — on the second episode of “How to Live With Your Parents (for the Rest of Your Life).” After her stepfather Max convinced her ex-husband that he needed to stop helping her so much, Polly threw her back out training for a 5K.

With Julian staying away, as requested, it fell to Max and Elaine to step up and take care of both Polly and her daughter, Natalie. And they hated every minute of it. It’s hard to imagine them ever raising a child. While they embrace the more fun aspects of being grandparents, all that responsibility quickly started to overwhelm them.

Sarah Chalke got to do some physical comedy, while revealing her character’s terrible claustrophobia. A montage of her trying to avoid going into an MRI machine was one of the highlights of the episode. The strength of the cast is one of the reasons the show brought in more than 8 million viewers with its premiere last week. Another reason is that “Modern Family” lead-in.

Read More…
More on Reality-Free

From: http://www.huffingtonpost.com/2013/04/11/live-with-your-parents-polly-mri-video_n_3058466.html

Preclinical Data Presented at AACR Describe a Mechanism of Action of Cabozantinib in a Prostate Canc

By Business Wirevia The Motley Fool

Filed under:

Preclinical Data Presented at AACR Describe a Mechanism of Action of Cabozantinib in a Prostate Cancer Bone Metastasis Model

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Exelixis, Inc. (NAS: EXEL) announced the presentation of preclinical data that provide insight into the mechanism of action of its lead compound, cabozantinib, with respect to its activity against prostate cancer tumors that have metastasized to the bone. Timothy Graham, a researcher at The Institute of Cancer Research in London, UK, presented the data (abstract #3924) today in a poster presentation session at the American Association for Cancer Research (AACR) Annual Meeting 2013, which is being held April 6-10, 2013, in Washington, D.C.

Previously reported clinical findings with cabozantinib in castration-resistant prostate cancer (CRPC) patients with bone metastases have included a 67% rate of bone scan response, reduced 99Tc-MDP uptake, and reductions in plasma markers of osteoclast activity. In addition, an increase in tumor apparent diffusion coefficient (ADC) measured using diffusion-weighted MRI was reported in a cabozantinib-treated CRPC patient with a bone scan response. Based on these observations, studies of cabozantinib in preclinical models of prostate cancer bone metastases were undertaken to understand the mechanism(s) of action underlying these effects.

In the poster presented today, the investigators reported on a refined prostate cancer bone metastasis model that develops many of the features associated with bone metastases in CRPC patients. In this model, injection of VCaP prostate cancer cells expressing luciferase (to allow bioluminescent imaging of tumors) into the tibiae of mice induced aberrant bone remodeling and development of tumor bone lesions. Both histological analysis of tissue sections and radiological imaging showed the development of extensive osteosclerosis, with abnormal new bone protruding from the tibiae as well as osteolysis resulting in destruction of normal bone structures. This was accompanied by increased numbers of osteoclasts at the sites of bone remodeling. A large increase in 99Tc-methylene diphosphonate (MDP) uptake was observed at the site of the bone lesions as measured by single photon emission computed tomography (SPECT) imaging. 99Tc-MDP bone scans are routinely employed in clinical practice to detect bone metastases in CRPC patients.

Treatment of tumor-bearing animals with cabozantinib resulted in rapid and substantial inhibition of tumor growth evident by both bioluminescent and magnetic resonance imaging (MRI) techniques. Monitoring tumors in cabozantinib-treated animals using diffusion-weighted MRI showed a significant increase in the apparent diffusion coefficient (ADC) compared to tumors in vehicle-treated animals. Increases in ADC are the result of increased mobility of water molecules in the tumor, and have been shown to correlate with tumor cell death. Consistent with these findings, histological …read more

Source: FULL ARTICLE at DailyFinance

Genzyme's Once-daily, Oral AUBAGIO® (teriflunomide) Approved in Argentina for the Treatment of Relap

By Business Wirevia The Motley Fool

Filed under:

Genzyme’s Once-daily, Oral AUBAGIO ® (teriflunomide) Approved in Argentina for the Treatment of Relapsing Multiple Sclerosis

Approval Expands Footprint of AUBAGIO Across Three Continents and Further Advances Genzyme’s Global MS Franchise

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today Argentina‘s National Administration of Drugs, Food and Medical Technology (ANMAT) has approved once-daily, oral AUBAGIO® 14 mg as a new treatment indicated for patients with relapsing forms of multiple sclerosis (MS).

“Studied in one of the largest clinical trial programs of any MS treatment, AUBAGIO has had consistent effects across all the important measures of MS disease activity including slowing the progression of disability, reducing the number of brain lesions as detected by MRI and reducing relapses. The clinical data supporting AUBAGIO confirm its importance as a new treatment option for MS patients,” said Dr. Jorge Correale, Head of Neuroimmunology and Demyelinating Diseases, Raul Carrea Institute for Neurological Research FLENI, Argentina.

The decision by ANMAT represents the first approval for once-daily, oral AUBAGIO in Latin America. AUBAGIO is also approved in both the United States and Australia, with additional marketing applications under review by regulatory authorities around the world.

“The approval in Argentina of once-daily, oral AUBAGIO represents another important advancement for the Genzyme MS Franchise,” said Bill Sibold, SVP, Head of MS Business, Genzyme. “Genzyme is committed to becoming leaders in MS and developing differentiated treatments that can address the diverse needs of the MS community. Now approved on three continents, AUBAGIO‘s established efficacy and convenient dosing can provide many patients with an attractive alternative to frequent and potentially burdensome injections.”

The ANMAT approval of AUBAGIO was based on safety and efficacy data from the TEMSO (TEriflunomide Multiple Sclerosis Oral) trial. The ongoing AUBAGIO clinical development program, involving more than 5,000 patients in 36 countries, is amongst the largest of any MS therapy. Some patients in extension trials have been treated for up to 10 years.

AUBAGIO, in its clinical studies, has shown favorable efficacy and a well-characterized safety profile. With its once-daily oral administration and tolerability, AUBAGIO should contribute positively to the care of patients with Multiple Sclerosis,” said Dr. Edgardo Cristiano, Head of the Neurology Department of the Hospital Italiano de Buenos Aires, Argentina.


AUBAGIO is an immunomodulator with anti-inflammatory properties. Although the exact mechanism of action for AUBAGIO …read more

Source: FULL ARTICLE at DailyFinance